According to a newly-issued report, the brain trust at PriceWaterhouseCoopers expects 2007 to be a signal year in the healthcare history. Among other things, they say, it should be the point at which states begin to take a lead role in reform and consumer-driven health initiatives reach the tipping point. With federal regulators at a standstill, PwC expects to see states jump into controversial issues such as stem cell research [1], health insurance expansion and pharma promotions [2]. States should also continue to promote transparency, though the programs are likely to remain inconsistent. Researchers also see next year as the acid test for CDHPs, with a "critical mass" of consumers enrolled in such plans. Other trends include significant price pressure on pharmaceuticals through generic introductions [3], a major focus on obesity reduction, and a newly retail-like feel to healthcare delivery as consumer-driven care matures.

For more information on this research:
- read the PwC release [4]
- download the PwC report [5] (.pdf)

Related Articles:
Democrats to push for generic biotech drugs. Report [6]
Drug makers to face many battles with Dems. Report [7]
State of the Union: Fat. Report [8]
Let he who is without conflict-of-interest cast the first stone. Editorial [9]